BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2026 7:28:51 AM | Browse: 33 | Download: 201
 |
Received |
|
2025-09-26 10:43 |
|
Peer-Review Started |
|
2025-09-26 10:43 |
|
First Decision by Editorial Office Director |
|
2025-12-02 10:00 |
|
Return for Revision |
|
2025-12-02 11:28 |
|
Revised |
|
2025-12-15 12:47 |
|
Publication Fee Transferred |
|
2025-12-22 12:59 |
|
Second Decision by Editor |
|
2026-01-26 02:58 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-26 08:34 |
|
Articles in Press |
|
2026-01-26 08:34 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-23 07:33 |
|
Publish the Manuscript Online |
|
2026-04-08 07:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
CD161+CD8+ T cells in patients with hepatitis B virus-associated hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chen-Rui Liu, Meng Zhang, Mu-Qi Wang, Wen Zhang, Jin Li, Gao-Zhao Shi, Fan-Fan Liang, Ya-Ping Li and Na Huang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Basic and Clinical Integration Project of Xi’an Jiaotong University |
YXJLRH2022067 |
| Shaanxi Provincial Basic Research Program in Natural Sciences |
2023-JC-647 |
| Shaanxi Provincial Basic Research Program in Natural Sciences |
2023-JC-QN-0918 |
|
| Corresponding Author |
Na Huang, PhD, Biological Diagnosis and Treatment Center, Second Affiliated Hospital of Xi’an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an City, Xi’an 710004, Shaanxi Province, China. huangna_428@163.com |
| Key Words |
CD8+ T cells; CD161; Programmed death receptor 1; Hepatitis B virus-associated hepatocellular carcinoma; Immunotherapy |
| Core Tip |
This study reveals elevated CD161+CD8+ T cells in peripheral blood of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) patients, correlating with disease progression. Programmed death receptor 1 (PD-1) inhibitors reduced PD-1+ subsets but did not alter CD161 expression, indicating CD161 operates independently of PD-1 pathways. Critically, CD161 protein overexpression in HCC tissues—exceeding paracancerous and chronic hepatitis B tissues—identifies it as a key immunosuppressive molecule. These findings position CD161 as a promising standalone immunotherapeutic target for enhancing T-cell function in HBV-HCC, beyond current PD-1 blockade strategies. |
| Publish Date |
2026-04-08 07:28 |
| Citation |
Liu CR, Zhang M, Wang MQ, Zhang W, Li J, Shi GZ, Liang FF, Li YP, Huang N. CD161+CD8+ T cells in patients with hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(4): 114547
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i4/114547.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i4.114547 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
